The mexico compounding pharmacies market is anticipated to reach USD 181.12 million by 2030 and is anticipated to expand at a compound annual growth rate (CAGR) of 5.02% from 2025-2030, according to a new report by Grand View Research, Inc. The increasing demand for personalized medicine is driven by the need to enhance treatment effectiveness, safety, and efficiency. The growing prevalence of chronic conditions, such as diabetes, cardiovascular diseases, and neurological disorders, is fueling the demand for customized formulations. Furthermore, compounding pharmacies are essential in improving medication adherence by addressing individual patient needs, including allergies, taste preferences, and dosage modifications. Therefore, the answer is: The increasing demand for personalized medicine, driven by the need for customized formulations and improved medication adherence, is propelling market growth.
The increasing accessibility of genetic testing and molecular profiling across the country allows healthcare professionals to tailor medications based on a patient’s genetic makeup. For instance, a July 2021 article in the World Journal of Oncology titled “Personalized Medicine in Ovarian Cancer: A Perspective from Mexico” highlighted how researchers identified molecular factors involved in the pathogenesis of ovarian cancer. This discovery enables patients to receive personalized diagnoses and assists healthcare providers in predicting effective treatments for the disease, ultimately improving the efficiency, cost-effectiveness, safety, and outcomes of healthcare.
Moreover, nutritional deficiencies in the population present lucrative growth opportunities for compounding pharmacies. According to the World Health Organization (WHO), nutritional deficiencies were responsible for 10,726 deaths in Mexico in 2021. Data from the National Health and Nutrition Survey 2021 reported alarming rates of overweight and obesity, affecting 37.4% of children (5–11 years old), 42.9% of adolescents (12–19 years old), and 72.4% of adults (20 years and older).
Request a free sample copy or view report summary: Mexico Compounding Pharmacies Market Report
On the basis of therapeutic area, the pain management segment held the largest market share in 2024. This can be attributed to the offering of customized medications tailored to the specific needs of individual patients.
On the basis of age cohort, the adult segment held the largest revenue share in 2024 due to the rising shift from reactive to preventive medicine.
On the basis of type, Pharmaceutical Ingredient Alteration (PIA) segment held the largest market share in 2024. This can be attributed to its quick response to shortages of certain medicines by reformulating available ingredients into effective alternatives.
On the basis of sterility, the sterile segment held the largest market share in 2024. This can be attributed to the rise in chronic diseases, healthcare and the aging population.
For this report, Grand View Research has segmented the Mexico compounding pharmacies market on the basis of therapeutic area, age cohort, type, and sterility.
Mexico Compounding Pharmacies Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)
Hormone replacement therapy
Pain management
Specialty drugs
Dermatology
Nutritional Supplements
Others
Mexico Compounding Pharmacies Age Cohort Outlook (Revenue, USD Million, 2018 - 2030)
Pediatric
Adult
Geriatric
Mexico Compounding Pharmacies Type Outlook (Revenue, USD Million, 2018 - 2030)
Pharmaceutical Ingredient Alteration (PIA)
Currently Unavailable Pharmaceutical Manufacturing (CUPM)
Pharmaceutical Dosage Alteration (PDA)
Others
Mexico Compounding Pharmacies Sterility Outlook (Revenue, USD Million, 2018 - 2030)
Sterile
Non sterile
List of Key Players in the Mexico Compounding Pharmacies Market
Fagron (Brands & Essentials)
Omicronlab
Magistral Pharmacies
BIOH
FarmaLife
Farmacia México
Pharma Tycsa
Compounding Wholesalers de México
MXPharmacy (Edge Pharma)
Farmacias el Globo
DermiCo
Bionorusso
Hervanario
"The quality of research they have done for us has been excellent..."